BioCryst Pharmaceuticals Inc. reported preliminary, unaudited net revenue for its flagship product ORLADEYO (berotralstat) of $601 million for the full year 2025, representing a 37 percent year-over-year increase and surpassing its prior guidance range of $590 million to $600 million
Preliminary, unaudited cash, cash equivalents, restricted cash & investments as of December 31, 2025, were $338 million.
Market Data 
Markets 
AI
